因特利亚制药

US · NTLA #2899 按市值排名上市于 2016

11.42 +0.08 +0.71%

实时 - 追踪5344个代码 - 心跳于314秒前 · 2026-10-16 19:55

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了2家。
机构持股总比例下降了2.9个百分点。

机构持股

机构持股比例: 101.67% -2.86pp
机构数量: 385 -2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund70.74%

Hedge Fund16.94%

Public Company7.17%

VC/PE Fund3.55%

Private Company2.69%

Individual/Insider1.62%

Government Pension Fund0.45%

Family Office/Trust0.13%

主要股东截至 2026-06-30

ARK Investment Management LLC 12.04% · 16.88M 股

BlackRock 11.00% · 15.41M 股

State Street Global Advisors 6.59% · 9.23M 股

Vanguard Portfolio Management, LLC 5.23% · 7.33M 股

Vanguard Capital Management, LLC 4.96% · 6.95M 股

D. E. Shaw & Co., L.P. 4.60% · 6.44M 股

Two Sigma Investments, LP 3.74% · 5.24M 股

FMR 3.40% · 4.76M 股

RA Capital Management, L.P. 3.23% · 4.53M 股

Regeneron Pharmaceuticals, Inc. 2.64% · 3.70M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 30次买入 · 20次卖出

姓名	职务	持股比例
John Leonard	Chief Executive Officer	0.86%
Fred Cohen	Independent Director	0.14%
Edward Dulac	Executive Vice President, Chief Financial Officer and Treasurer	0.11%
William Chase	Independent Director	0.10%
Eliana Clark	Executive Vice President	0.07%
David Lebwohl	Chief Medical Officer	0.06%
James Basta	General Counsel	0.05%
Michael Dube	VP, CAO & principal accounting officer	0.05%
Birgit Schultes	Senior VP & Head of Cell Therapies	0.05%
Derek Hicks	Executive VP & Chief Business Officer	0.04%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-20	John Leonard	Chief Executive Officer	Automatic Disposition	-22,675	$12.60–13.00
2026-08-19	John Leonard	Chief Executive Officer	Intent to Sell (Form 144)	-22,675	$12.95
2026-07-21	Edward Dulac	Executive Vice President, Chief Financial Officer and Treasurer	Open Market Disposition	-8,111	$11.25
2026-07-01	Edward Dulac	Executive Vice President, Chief Financial Officer and Treasurer	Automatic Disposition	-4,677	$18.00
2026-06-30	Michael Dube	VP, CAO & principal accounting officer	Open Market Disposition	-2,641	$16.78
2026-06-08	Fred Cohen	Independent Director	Other Acquisition	+9,200	--
2026-06-08	Fred Cohen	Independent Director	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	Franciscus A. G. Verwiel	Independent Chairperson	Other Acquisition	+9,200	--
2026-06-08	Franciscus A. G. Verwiel	Independent Chairperson	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	William Chase	Independent Director	Other Acquisition	+9,200	--
2026-06-08	William Chase	Independent Director	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	Brian Goff	Director	Other Acquisition	+9,200	--
2026-06-08	Brian Goff	Director	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	Jesse Goodman	Independent Director	Other Acquisition	+9,200	--
2026-06-08	Jesse Goodman	Independent Director	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	Georgia Keresty	Independent Director	Other Acquisition	+9,200	--
2026-06-08	Georgia Keresty	Independent Director	Other Derivative Acquisition	+13,300	$12.89
2026-06-08	Muna Bhanji	Independent Director	Other Acquisition	+9,200	--
2026-06-08	Muna Bhanji	Independent Director	Other Derivative Acquisition	+13,300	$12.89
2026-03-01	James Basta	General Counsel	Open Market Disposition	-1,211	$13.78

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:55:36 · 仅供参考，不构成投资建议，也未考虑您的具体情况。